Biopharmaceutical CMO Market Size & Growth:

The Biopharmaceutical CMO Market size is estimated at USD 21.16 billion in 2025 and is expected to reach USD 76.20 billion by 2035, growing at a CAGR of 13.67% over the forecast period of 2026-2035.

The global biopharmaceutical CMO market trend is a growing demand for contract manufacturing and development services such as biologics production, biosimilar manufacturing, and process optimization platforms as the growth of the market is driven by increasing pharmaceutical outsourcing strategies, rising development costs for biologic drugs, and capacity constraints at pharmaceutical companies. Also driven by a growing adoption of mammalian cell culture technologies and the growing focus on specialized manufacturing capabilities as biopharmaceutical companies become more focused on core competencies and are more willing to invest in strategic partnerships with contract manufacturing organizations, resulting in growth in the domestic and international market for monoclonal antibody production and recombinant protein manufacturing solutions.

For instance, in March 2024, growing demand for biologic therapies and improved manufacturing infrastructure drove a 24% increase in biopharmaceutical CMO service contracts globally, boosting production capacity utilization and advanced therapy development adoption.

Biopharmaceutical CMO Market Size and Forecast:

• Market Size in 2025: USD 21.16 billion

• Market Size by 2035: USD 76.20 billion

• CAGR: 13.67% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get More Information on Biopharmaceutical CMO Market - Request Sample Report

Biopharmaceutical CMO Market Trends

• Biopharmaceutical CMO services are being adopted because pharmaceutical companies demand flexible manufacturing capacity, specialized expertise in complex biologics production, and cost-effective development solutions.

• Customized manufacturing platforms based on product complexity, scale requirements, and regulatory specifications to improve production efficiency and therapeutic outcomes.

• The development of single-use bioreactor systems, continuous manufacturing technologies, and advanced cell culture platforms to improve production yields and reduce contamination risks and operational costs.

• Integrated services including process development, analytical testing, and regulatory support are all available to ensure seamless technology transfer and commercialization timelines.

• Increased demand for modular manufacturing facilities, multi-product capabilities and dedicated production suites to help capacity flexibility and product segregation requirements.

• Collaboration between biopharmaceutical companies, contract development and manufacturing organizations and technology providers to develop innovative production methodologies and improve manufacturing efficiency.

• FDA, EMA and regulatory authorities promoting standards for good manufacturing practices, biosimilar development guidelines, and advanced therapy manufacturing requirements.

The U.S. Biopharmaceutical CMO Market is estimated at USD 8.32 billion in 2025 and is expected to reach USD 29.96 billion by 2035, growing at a CAGR of 13.74% from 2026-2035. The United States represents the largest market for biopharmaceutical contract manufacturing, primarily driven by the extensive biologics development pipeline, established regulatory framework for biopharmaceutical manufacturing, and well-developed contract manufacturing infrastructure. Investment in advanced manufacturing technologies, strong venture capital funding for biotechnology startups and increased pharmaceutical company outsourcing strategies help to drive growth in the market.

Biopharmaceutical CMO Market Growth Drivers:

• Rising Biologics Development and Capacity Constraints are Driving the Biopharmaceutical CMO Market Growth

Rising biologics development and capacity constraints take the center stage as a growth driver for the biopharmaceutical CMO market share, and are driven by the increasing therapeutic antibody approvals, complex manufacturing requirements, and limited in-house production capabilities at pharmaceutical companies for specialized biologic modalities. These solutions for outsourced manufacturing and process development are driving the base of the market, the penetration of contract manufacturing & contract research markets, and adding to the overall market share globally.

For instance, in June 2024, mammalian cell-based and integrated CMO service platforms accounted for ~64% of the total global biopharmaceutical outsourcing investments, reflecting growing industry preference and expanding market share.

Biopharmaceutical CMO Market Restraints:

• Quality Control Concerns and Technology Transfer Challenges are Hampering the Biopharmaceutical CMO Market Growth

Quality control concerns & technology transfer challenges of biopharmaceutical manufacturing also restrict the biopharmaceutical CMO market growth, as a large number of pharmaceutical companies face difficulties ensuring consistent product quality, managing intellectual property protection, and maintaining process reproducibility across different manufacturing sites. This might lead to production delays, regulatory compliance issues, and reduced confidence in outsourcing partnerships. As a result, drug development timelines suffer, and market growth is stunted in regions where manufacturing expertise is limited and quality assurance infrastructure is underdeveloped.

Biopharmaceutical CMO Market Opportunities:

• Biosimilar Development and Emerging Markets Expansion Drive Future Growth Opportunities for the Biopharmaceutical CMO Market

The opportunity in the biosimilar development and emerging markets expansion in biopharmaceutical CMO market is in the form of cost-effective manufacturing solutions, accelerated development timelines, and regulatory pathway expertise for biosimilar products. These solutions provide for improved access to biologic therapies, competitive pricing strategies, and expanded patient populations in developing economies. Through enhanced manufacturing scalability, regional production capabilities, and regulatory knowledge transfer, particularly in areas with growing healthcare expenditure and biosimilar adoption, these technologies may improve market accessibility, decrease treatment costs, and expand the market.

For instance, in April 2024, industry reports indicated that 71% of biopharmaceutical companies planned to increase CMO partnerships for biosimilar development, highlighting rising collaboration trends and increasing demand for specialized contract manufacturing services.

Biopharmaceutical CMO Market Segment Analysis

• By source, mammalian held the largest share of around 67.42% in 2025, and is expected to register the highest growth with a CAGR of 13.89%.

• By service, the contract manufacturing segment dominated the market with approximately 63.28% share in 2025, while contract research is expected to register the highest growth with a CAGR of 14.12%.

• By product, biologics accounted for the leading share of nearly 58.94% in 2025, and is expected to register the highest growth with a CAGR of 13.92%.

By Source, Mammalian Leads the Market, While Mammalian Registers Fastest Growth

The mammalian segment accounted for the highest revenue share of approximately 67.42% in 2025, owing to superior post-translational modification capabilities, established regulatory pathways for mammalian cell-derived therapeutics, and strong pharmaceutical industry preference for Chinese hamster ovary (CHO) cell systems. Emerging trends, including increasing requirements for complex glycosylation patterns and monoclonal antibody production experience. In comparison, the mammalian segment is anticipated to achieve the highest CAGR of nearly 13.89% during the 2026–2035 period, driven by the continuous advancement in cell line development technologies, growing therapeutic antibody pipeline, and expanding biosimilar manufacturing requirements. Drivers include rising adoption of high-producing cell lines, the preference for consistent protein expression systems.

By Service, the Contract Manufacturing Segment dominates, while the Contract Research Segment Shows Rapid Growth

By 2025, the contract manufacturing segment contributed the largest revenue share of 63.28% due to extensive capacity requirements for commercial-scale production, established manufacturing infrastructure and growing pharmaceutical outsourcing strategies. Growing adoption of dedicated biologics facilities coupled with regulatory compliance expertise, biopharmaceutical companies are increasingly outsourcing production activities. The contract research segment is projected to grow at the highest CAGR of about 14.12% between 2026 and 2035 due to the growing need for specialized development services and early-stage product optimization capabilities. Some of the reasons include better access to advanced analytical platforms, improved development timeline acceleration, and biotechnology startups' preference for risk-sharing partnerships with experienced contract research organizations.

By Product, Biologics Lead, and Registers Fastest Growth

The biologics segment accounted for the largest share of the biopharmaceutical CMO market with about 58.94%, owing to their dominant position in pharmaceutical pipelines, complex manufacturing requirements, and substantial investment in therapeutic development programs. Reasons driving the biologics segment include increasing monoclonal antibody approvals and recombinant protein commercialization needs. In addition, it is slated to grow at the fastest rate with a CAGR of around 13.92% throughout the forecast period of 2026–2035, as pharmaceutical companies seek comprehensive manufacturing solutions for antibody-drug conjugates, novel biologic modalities, and personalized medicine applications. Increased focus on vaccine development and cell therapy manufacturing contribute to their adoption, while improved production technologies and regulatory framework maturation drive continued investment.

Biopharmaceutical CMO Market Regional Highlights:

Asia Pacific Biopharmaceutical CMO Market Insights:

Asia Pacific is the fastest-growing segment in the biopharmaceutical CMO market with a CAGR of 15.23%, as the awareness about cost-effective manufacturing solutions, government biotechnology development initiatives, and pharmaceutical manufacturing capacity expansion in developing nations is growing. Factors including rapid biosimilar market development, rising contract manufacturing investment with favorable regulatory environments, and growing adoption of international quality standards are stimulating the market growth. Manufacturing infrastructure modernization and skilled workforce availability have been instrumental in improving production capabilities, especially in countries with emerging biopharmaceutical industries. Strategic partnerships and technology transfer programs also help in advancing manufacturing excellence and global supply chain integration. Increase in demand in Asia Pacific region owing to rising healthcare investment against historical spending levels and growing affordability and accessibility of advanced biomanufacturing technologies.

Do You Need any Customization Research on Biopharmaceutical CMO Market - Enquire Now

North America Biopharmaceutical CMO Market Insights:

North America held the largest revenue share of over 43.67% in 2025 of the biopharmaceutical CMO market due to an established contract manufacturing infrastructure, extensive biologics development pipeline, and increased pharmaceutical company reliance on outsourcing strategies for specialized production. Drivers include ubiquitous use of mammalian cell culture technologies, an advanced biotechnology ecosystem, growing venture capital investment and greater acceptance of contract manufacturing partnerships stemming from capacity optimization needs. At the same time, various government funding programs, FDA regulatory clarity and enormous investments in single-use manufacturing systems from CMO providers are anchoring biopharmaceutical contract services in the market, and ensuring multibillion dollar revenues around the world.

Europe Biopharmaceutical CMO Market Insights:

The biopharmaceutical CMO market in Europe is the second-dominating region after North America on account of an increase in the adoption of biosimilar development programs, robust pharmaceutical manufacturing standards including EMA guidelines, and increasing strategic outsourcing initiatives across biopharmaceutical companies. Rising implementation of advanced manufacturing technologies, strong contract development organization presence, favorable government support for biotechnology innovation, and cross-border manufacturing collaborations are also contributing to the sustained growth of the market in leading European countries.

Latin America (LATAM) and Middle East & Africa (MEA) Biopharmaceutical CMO Market Insights:

In Latin America, and Middle East & Africa, the growing biopharmaceutical sector development and increase in manufacturing infrastructure investment with biosimilar market expansion support the biopharmaceutical CMO market growth. The rising popularity of cost-competitive manufacturing solutions and regional regulatory harmonization efforts, along with international pharmaceutical company partnerships, will aid local production capabilities and technology transfer. The increasing healthcare access priorities and improving manufacturing quality standards in these regions are continuing to encourage market growth.

Biopharmaceutical CMO Market Competitive Landscape:

Lonza Group AG (est. 1897) is a leading contract development and manufacturing organization that focuses on integrated biopharmaceutical solutions for small molecule and biologics production. It uses its comprehensive manufacturing network and advanced technology platforms to produce cutting-edge contract manufacturing services with seamless process development and commercial production integration.

• In February 2025, it expanded its mammalian cell culture manufacturing capabilities with next-generation bioreactor systems and AI-driven process optimization, aiming to improve production efficiency and capacity utilization across its global manufacturing network.

Samsung Biologics Co., Ltd. (est. 2011) is a well-known global contract manufacturing organization focused on large-scale biologics production, process development, and analytical services. It invests in state-of-the-art manufacturing facilities and continuous bioprocessing technologies with the hopes of revolutionizing biopharmaceutical production with efficient, scalable, and cost-effective manufacturing solutions.

• In May 2024, launched an enhanced integrated service platform featuring accelerated technology transfer and dedicated production suites across Asian manufacturing facilities, enhancing client flexibility, production timelines, and biosimilar development capabilities.

Catalent, Inc. (est. 2007) is a leading global provider in the fields of biologics development, cell and gene therapy manufacturing, and pharmaceutical delivery technologies. The company's contract manufacturing product portfolio focuses on flexible manufacturing platforms and advanced modalities support, and features a strong commitment to quality excellence and continuous innovation to complement the strong market presence in both clinical and commercial manufacturing settings.

• In September 2024, introduced advanced gene therapy manufacturing capabilities and expanded cell culture capacity for its biologics platform, strengthening development service offerings and expanding adoption among emerging biotechnology companies.

Biopharmaceutical CMO Market Key Players:

• Lonza Group AG

• Samsung Biologics Co., Ltd.

• Catalent, Inc.

• Boehringer Ingelheim International GmbH

• Thermo Fisher Scientific Inc.

• WuXi Biologics (Cayman) Inc.

• Fujifilm Diosynth Biotechnologies

• AGC Biologics

• Rentschler Biopharma SE

• Recipharm AB

• Abzena plc

• ProBioGen AG

• Binex Co., Ltd.

• Celonic AG

• Cytiva (Danaher Corporation)

• KBI Biopharma, Inc.

• Evonik Industries AG

• Paragon Bioservices, Inc.

• BIOTEC Services International Ltd.

• Wacker Chemie AG

• Batavia Biosciences

• Richter-Helm BioLogics GmbH & Co. KG

• CMC Biologics A/S

• AbbVie Contract Manufacturing

• Emergent BioSolutions Inc.